NHS England has issued preliminary market engagement for Project Revive, an upcoming National Generic Pharmaceuticals framework focused on secondary-care supply chain resilience. The programme is being developed with the MHRA and Medicines UK and is intended to support new supply routes for strategically important medicines.
This is a specialist pharmaceutical opportunity, not a broad healthcare or social care framework. It is most relevant to manufacturers, Marketing Authorisation holders and pharmaceutical supply partners that can support critical generic medicine availability. If you are assessing whether Project Revive fits your portfolio, contact Thornton & Lowe.
What Project Revive is trying to achieve
Project Revive was announced as part of the Government's Supply Resilience Strategy. NHS England describes it as a programme to strengthen patient access and secondary-care supply resilience by reactivating dormant or currently unmarketed MHRA-approved Marketing Authorisations for critical products and by seeking new supply routes in strategically important areas.
The notice also says the programme is intended to support supply from late 2026 and early 2027. Specific products are not yet listed in the market engagement notice and are expected to be provided in the Invitation to Tender. Suppliers should therefore avoid assuming that the framework is a route for all generic pharmaceuticals.
Framework timetable
The planned framework is expected to start on 1 April 2027 and run for an initial 22 months to 31 January 2029, with an option to extend to a maximum total contract length of 48 months. The notice lists regional groupings covering DCE/DSW, DLS/DNE and DLN/DNW.
The market engagement closes on 25 August 2026, with the tender notice currently estimated for 26 August 2026. The opportunity is identified as suitable for SMEs.
One field in the notice shows a total value of £1 excluding VAT. This is clearly not a meaningful estimate of the commercial opportunity, so suppliers should not use it to assess potential framework spend. The practical commercial assessment will need to wait for the product detail and tender documents.
Current information is available in the Project Revive Find a Tender notice.
Who should prepare?
Potential bidders should focus on their ability to support resilient supply of the products eventually included in the ITT. Evidence may need to cover regulatory status, manufacturing or sourcing capacity, quality systems, continuity planning, stock and lead-time management, distribution, shortage response and the ability to scale supply safely.
Because NHS pharmaceutical procurement is highly compliance-led, it is worth checking corporate and procurement evidence early. Our NHS procurement process guide provides a broader supplier view of the stages and evidence involved in NHS tendering.
Avoid overcommitting before the ITT
The biggest limitation at this stage is the lack of product-specific detail. The framework could be strategically important for suppliers with relevant licences and capacity, but the bid/no-bid decision should ultimately be tested against the final product list, commercial terms and supply obligations.
Use the engagement period to identify the products and supply routes you could credibly support, then prepare the underlying regulatory, capacity and resilience evidence so that it can be adapted quickly once the ITT is available.
Preparing for Project Revive
Thornton & Lowe can help suppliers review the tender when it is issued, structure compliance evidence and develop clear quality responses. Talk to our NHS bid team if Project Revive is likely to be a target.
